We've found
13,253
archived clinical trials in
Arthritis
We've found
13,253
archived clinical trials in
Arthritis
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials